Kohjin Bio Co.,Ltd. (JP:177A)

:177A

177A

Kohjin Bio Co.,Ltd.

RESEARCH TOOLSreports

Want to see JP:177A full AI Analyst Report?

Kohjin Bio Co.,Ltd. (177A) Price & Analysis

0 Followers

177A Stock Chart & Stats

¥1525.00

-¥17.00(-1.03%)

At close: Jan 08 4:00 PM EST

¥1525.00

-¥17.00(-1.03%)

Day’s Range― - ―

52-Week Range¥1,151.00 - ¥2,020.00

Previous CloseN/A

Volume7.50K

Average Volume (3M)3.64K

Market Cap

¥7.53B

Enterprise Value¥7.22B

Total Cash (Recent Filing)¥3.10B

Total Debt (Recent Filing)¥1.99B

Price to Earnings (P/E)24.5

Beta0.82

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.62%

Share Statistics

EPS (TTM)15.18

Shares Outstanding5,111,600

10 Day Avg. Volume4,170

30 Day Avg. Volume3,643

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)1.55

Price to Sales (P/S)1.72

P/FCF Ratio318.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)¥5.58B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA high equity ratio (63.78%) and low debt-to-equity (0.41) indicate durable capitalization and limited leverage exposure. With ROE at 13.75% the company efficiently uses shareholder capital, providing long-term financial flexibility to fund R&D, absorb shocks, and pursue strategic investments without heavy refinancing risk.

Margin SustainabilityRobust gross and operating margins (gross 45.44%, EBIT 19.04%, EBITDA 27.01%) and a healthy net margin (15.26%) point to structural pricing power and operational efficiency. Such sustained margins support reinvestment in product development and create a buffer to protect profitability through industry cycles over months to years.

Improving Cash GenerationOperating cash flow converts earnings effectively (OCF/net income 1.15) and free cash flow is growing (7.52%), indicating improving cash conversion. Over a multi-month horizon this enhances the firm's ability to fund capex, reduce leverage, and support strategic initiatives without heavy dependence on external capital.

Bears Say

Top-line InstabilityReported revenue growth in fundamentals is negative (-1.44%), signaling top-line pressure that can erode scale benefits and limit capacity to expand R&D or commercial efforts. Persistent or recurring revenue declines reduce predictability of cash generation and constrain long-term growth planning over the coming quarters.

Earnings DeclineA significant EPS decline (-20.17%) points to material earnings pressure versus prior periods. Even with healthy margins reported, falling EPS can reflect one-off impacts or underlying demand/price pressures; continued EPS contraction would impair reinvestment, dividend capacity, and investor confidence over a medium-term horizon.

Operational VolatilityThe income statement notes EBIT volatility across years, which reduces earnings visibility and raises execution risk. Persistent operational swings make budgeting, capacity planning and long-term investments harder, increasing the probability of earnings misses or reactive cost cuts that could impair strategic initiatives over several quarters.

177A FAQ

What was Kohjin Bio Co.,Ltd.’s price range in the past 12 months?

Kohjin Bio Co.,Ltd. lowest stock price was ¥1151.00 and its highest was ¥2020.00 in the past 12 months.

What is Kohjin Bio Co.,Ltd.’s market cap?

Kohjin Bio Co.,Ltd.’s market cap is ¥7.53B.

When is Kohjin Bio Co.,Ltd.’s upcoming earnings report date?

Kohjin Bio Co.,Ltd.’s upcoming earnings report date is May 20, 2026 which is in 18 days.

How were Kohjin Bio Co.,Ltd.’s earnings last quarter?

Kohjin Bio Co.,Ltd. released its earnings results on Feb 13, 2026. The company reported ¥15.18 earnings per share for the quarter, beating the consensus estimate of N/A by ¥15.18.

Is Kohjin Bio Co.,Ltd. overvalued?

According to Wall Street analysts Kohjin Bio Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kohjin Bio Co.,Ltd. pay dividends?

Kohjin Bio Co.,Ltd. pays a Notavailable dividend of ¥24 which represents an annual dividend yield of 1.62%. See more information on Kohjin Bio Co.,Ltd. dividends here

What is Kohjin Bio Co.,Ltd.’s EPS estimate?

Kohjin Bio Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kohjin Bio Co.,Ltd. have?

Kohjin Bio Co.,Ltd. has 5,111,600 shares outstanding.

What happened to Kohjin Bio Co.,Ltd.’s price movement after its last earnings report?

Kohjin Bio Co.,Ltd. reported an EPS of ¥15.18 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.548%.

Which hedge fund is a major shareholder of Kohjin Bio Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:177A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kohjin Bio Co.,Ltd.

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums. In addition, the company offers normal human blood, serum, and plasma; pathological human serum; preserved animal blood; defibrinated and hemolyzed animal blood; animal serum and plasma; and other custom-designed products, such as eagle medium. Further, the company engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. The company was incorporated in 1981 and is based in Sakado, Japan.